Head-to-head Comparison of the Safety and Efficacy Profiles of Three Phosphodiesterase Type 5 Inhibitors through Patient-reported Outcomes of 130 000 Patients from a Direct-to-consumer Platform Database

Q: What type of study is this?

This is a Human Clinical Trial study.

Severin Rodler; Moritz von Büren; Marie-Luise Weiss; Johannes Huber; Ruth Himmelsbach; Florian Schröder; Edward Garrahy; Philipp Nuhn; Christian Gratzke; Christian Wülfing; Johannes von Büren; Severin Rodler; Moritz von Büren; Marie-Luise Weiss; Johannes Huber; Ruth Himmelsbach; Florian Schröder; Edward Garrahy; Philipp Nuhn; Christian Gratzke; Christian Wülfing; Johannes von Büren

doi:10.1016/j.euf.2025.11.006

Key Points

This research aims to compare the efficacy and safety of three phosphodiesterase type 5 inhibitors using patient-reported outcomes.
Analyzed data from a direct-to-consumer platform involving 130,000 patients.
Assessed efficacy and adverse event profiles of various PDE5 inhibitors.
Utilized real-world data to guide treatment recommendations.
Identified distinct efficacy profiles between the phosphodiesterase type 5 inhibitors.
Reported adverse events varied among different inhibitors.
Findings provide insights for urologists on treatment recommendations.

Implication

Direct-to-consumer platform data shows differing efficacy of phosphodiesterase type 5 inhibitors, implying new treatment recommendations.

Abstract

PDE5i usage is associated with distinct efficacy and AE profiles in a large real-world dataset guiding treatment recommendations for urologists. Future DTC data might be used to complement clinical trial data.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rodler et al. (2025) studied this question.

synapsesocial.com/papers/69254f7dc0ce034ddc3590e8 https://doi.org/10.1016/j.euf.2025.11.006

View Full Paper

Ask AI

Bookmark

Share

Head-to-head Comparison of the Safety and Efficacy Profiles of Three Phosphodiesterase Type 5 Inhibitors through Patient-reported Outcomes of 130 000 Patients from a Direct-to-consumer Platform Database

Key Points

Implication

Abstract

Discussion

Cite This Study

Head-to-head Comparison of the Safety and Efficacy Profiles of Three Phosphodiesterase Type 5 Inhibitors through Patient-reported Outcomes of 130 000 Patients from a Direct-to-consumer Platform Database

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from European Urology Focus

Keep reading

More related papers

More from European Urology Focus